Inhibitory effect of Fuzheng Huaji Decoction against non-small cell lung cancer cells in vitro and the possible molecular mechanism.
10.12122/j.issn.1673-4254.2025.06.04
- Author:
Lijun HE
1
;
Xiaofei CHEN
1
;
Chenxin YAN
1
;
Lin SHI
1
Author Information
1. School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China.
- Publication Type:Journal Article
- Keywords:
Fuzheng Huaji Decoction;
in vitro experiments;
molecular docking;
network pharmacology;
non-small cell lung cancer
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/metabolism*;
Drugs, Chinese Herbal/pharmacology*;
Cell Proliferation/drug effects*;
Apoptosis/drug effects*;
Lung Neoplasms/metabolism*;
A549 Cells;
Proto-Oncogene Proteins c-akt/metabolism*;
Protein Interaction Maps;
Signal Transduction/drug effects*;
Cell Line, Tumor
- From:
Journal of Southern Medical University
2025;45(6):1143-1152
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the inhibitory effect of Fuzheng Huaji Decoction against non-small cell lung cancer (NSCLC) cells in vitro and explore the underlying mechanism.
METHODS:The active ingredients and targets of Fuzheng Huaji Decoction were identified using TCMSP and SwissTargetPrediction databases. NSCLC-related targets from GeneCards and PharmGKB were intersected with the targets of the Decoction, and a protein-protein interaction (PPI) network was constructed to identify the core targets, which were analyzed with GO and KEGG pathway enrichment analysis. Cultured A549 cells were treated with different concentrations of Fuzheng Huaji Decoction-medicated serum, and the changes in cell proliferation, apoptosis, and protein expressions were examined using CCK-8 assay, annexin V-FITC/PI staining and Western blotting.
RESULTS:Fuzheng Huaji Decoction contained 140 active ingredients, and 707 drug-disease intersecting targets were identified. Among these targets, TP53, AKT1, HIF1A, GAPDH, ALB, EGFR, CTNNB1, and TNF were identified as the core targets which were involved in the biological processes related to kinases and receptors and the PI3K-AKT, Ras, calcium, and MAPK pathways. Molecular docking studies indicated strong binding affinity of the active ingredients with TP53, AKT1, and HIF1A. In cultured A549 cells, treatment with 2.5%, 5%, and 10% Fuzheng Huaji Decoction-medicated serum significantly inhibited cell proliferation, promoted cell apoptosis, and downregulated the expression levels of HIF1A, p-AKT (Thr308), and TP53 proteins.
CONCLUSIONS:Fuzheng Huaji Decoction inhibits proliferation of NSCLC cells possibly by downregulating the expressions of HIF1A, p-AKT (Thr308), and TP53.
